Replimune’s chief commercial officer sells $30,179 in stock

In a recent transaction, Christopher Sarchi, the Chief Commercial Officer of Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company with a market capitalization of $672 million, sold 3,749 shares of the company’s common stock. The stock has shown significant volatility, gaining nearly 12% in the past week despite being down over 40% in the last six months. The shares were sold at a weighted average price of $8.05, totaling approximately $30,179. This sale was executed to cover tax withholding obligations related to the partial vesting of Sarchi’s Restricted Stock Units, as per the "sell to cover" provision in the award agreements. Following the transaction, Sarchi retains ownership of 128,296 shares in the company. According to InvestingPro analysis, Replimune maintains a strong liquidity position with a current ratio of 11.43, and holds more cash than debt on its balance sheet. For deeper insights into Replimune’s financial health and 8 additional key ProTips, explore the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Replimune Group Inc . reported its first-quarter earnings for 2025, revealing a significant miss on expected earnings per share (EPS). The company posted an EPS of -$3.07, which fell short of the anticipated -$0.72. Despite the earnings miss, Replimune’s cash and cash equivalents increased to $483.8 million, extending its cash runway into the fourth quarter of 2026. The company is actively preparing for the potential commercialization of its product, RP-one, which has received breakthrough therapy designation and has a PDUFA date set for July 2025. Operational expansions include a new manufacturing facility and a 60-person commercial team. Analysts have noted the company’s increased personnel and operational costs in preparation for the commercial launch of RP-one. Moreover, Replimune remains engaged with the FDA and has completed late-cycle meetings and manufacturing inspections. The company plans to present additional data at the upcoming ASCO conference and is focused on enrolling patients in the IGNITE-three trial.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.